ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för lixisenatide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

49 träffar

Bibliografisk träff 2014-07-18

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.

Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M.

J Diabetes Complications · meta-analysis; research support, non-u.s. gov't; journal article · DOI 10.1016/j.jdiacomp.2014.07.007

Bibliografisk träff 2014-07-16

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.

Bain SC.

Diabetes Ther · review-article; journal article · DOI 10.1007/s13300-014-0073-z

Bibliografisk träff 2014-06-05

Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.

Ahrén B, Vorokhobina N, Souhami E, Demil N, Ye J, Aronson R.

J Diabetes Complications · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jdiacomp.2014.05.012

Bibliografisk träff 2014-06-01

[Lixisenatide (Lyxumia), subcutaneous].

Författaruppgift saknas

J Pharm Belg · journal article

Bibliografisk träff 2014-04-11

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ.

Diabetes Obes Metab · meta-analysis; research support, non-u.s. gov't; journal article · DOI 10.1111/dom.12290

Bibliografisk träff 2014-02-27

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.

Cai HY, Hölscher C, Yue XH, Zhang SX, Wang XH, Qiao F, Yang W, Qi JS.

Neuroscience · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuroscience.2014.02.022

Bibliografisk träff 2014-02-24

A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.

Schmidt LJ, Habacher W, Augustin T, Krahulec E, Semlitsch T.

Diabetes Obes Metab · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.1111/dom.12269

Bibliografisk träff 2014-02-01

[Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action].

Scheen AJ.

Rev Med Liege · journal article

Bibliografisk träff 2014-01-20

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.

Bolli GB, Owens DR.

Diabetes Obes Metab · research support, non-u.s. gov't; review; journal article · DOI 10.1111/dom.12253

Bibliografisk träff 2014-01-01

Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.

Stauder U, Enginee D, Elton H, Penfornis A, Edelman S.

J Diabetes Sci Technol · research-article; journal article · DOI 10.1177/1932296813511733

Bibliografisk träff 2013-12-13

Lixisenatide as add-on therapy to basal insulin.

Brown DX, Butler EL, Evans M.

Drug Des Devel Ther · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.2147/dddt.s45108

Bibliografisk träff 2013-10-19

A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.

Wilkins JJ, Dubar M, Sébastien B, Laveille C.

J Clin Pharmacol · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jcph.192

Bibliografisk träff 2013-09-01

Lixisenatide for the treatment of type 2 diabetes.

Petersen AB, Knop FK, Christensen M.

Drugs Today (Barc) · comparative study; review; journal article · DOI 10.1358/dot.2013.49.9.2020940

Bibliografisk träff 2013-08-28

Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.

Werner U.

J Diabetes Complications · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.jdiacomp.2013.06.003

Bibliografisk träff 2013-06-17

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.

Petersen AB, Christensen M.

Diabetes Metab Syndr Obes · review-article; journal article · DOI 10.2147/dmso.s45379

Bibliografisk träff 2013-03-28

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.

Wohlfart P, Linz W, Hübschle T, Linz D, Huber J, Hess S, Crowther D, Werner U, Ruetten H.

J Transl Med · research-article; journal article · DOI 10.1186/1479-5876-11-84

Bibliografisk träff 2013-03-01

Lixisenatide: first global approval.

Elkinson S, Keating GM.

Drugs · review; journal article · DOI 10.1007/s40265-013-0033-3

Bibliografisk träff 2011-03-11

Lixisenatide for type 2 diabetes mellitus.

Christensen M, Knop FK, Vilsbøll T, Holst JJ.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2011.562191

Bibliografisk träff 2009-08-01

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Christensen M, Knop FK, Holst JJ, Vilsboll T.

IDrugs · review; journal article